Oculis to Provide Update on DIAMOND Phase 3 Program for OCS-01 Eye Drops at Innovate Retina and Eyecelerator 2024
Oculis announced an update on its DIAMOND phase 3 program for OCS-01, a high-concentration dexamethasone eye drop formulated with OPTIREACH technology for the treatment for diabetic macular edema (DME).
David Eichenbaum, MD, an expert in retina diseases, will present new insights from Stage 1 of the DIAMOND trial at Innovate Retina on October 17, 2024. Dr. Eichenbaum’s talk, titled "OCS-01: Novel Topical Approach for Macular Edema," will highlight the positive results from Week 12 of Stage 1 and preview the design of Stage 2, which is aimed at evaluating the safety and efficacy of OCS-01 through Week 52. Both ongoing trials (DIAMOND-1 and DIAMOND-2) are set to enroll 350 patients each.
On the same day, Oculis’ Chief Executive Officer, Riad Sherif, MD, will speak at Eyecelerator 2024 during the Retina Showcase session. Dr. Sherif will discuss the broader impact of OCS-01 for DME and share key updates, including upcoming milestones for Oculis’ ACUITY phase 2 trial with OCS-05, a treatment for acute optic neuritis, with topline results expected by the end of 2024.
Eyecelerator 2024 Presentation Details
- Presenter: Riad Sherif, MD, Chief Executive Officer, Oculis
- Session: Retina Showcase
- Presentation Time: October 17, 2024, 2:06 pm CT
- Location: McCormick Place, Chicago, IL
Innovate Retina Presentation Details
- Presenter: David Eichenbaum, MD, Partner and Director of Research at Retina Vitreous Associates of Florida
- Session: New Routes and New Molecules
- Presentation Time: October 17, 2024, 5:31 pm CT
- Location: InterContinental Chicago Magnificent Mile, Chicago, IL
OCS-01 eye drops represent a novel, noninvasive treatment option for patients with DME, offering a topical alternative to injections currently used to manage the disease. Early-stage results from the DIAMOND program have shown promising efficacy, and the ongoing trials are expected to provide critical data on long-term safety and effectiveness, according to Oculis.